Retrophin, Inc. (NASDAQ:RTRX) has earned an average rating of “Buy” from the seven analysts that are covering the company, MarketBeat.com reports. Two investment analysts have rated the stock with a hold recommendation, three have given a buy recommendation and one has given a strong buy recommendation to the company. The average 1 year price target among brokerages that have issued a report on the stock in the last year is $36.50.
RTRX has been the subject of several research analyst reports. ValuEngine downgraded shares of Retrophin from a “hold” rating to a “sell” rating in a research note on Friday, June 2nd. BidaskClub raised shares of Retrophin from a “buy” rating to a “strong-buy” rating in a research note on Thursday, August 24th.
COPYRIGHT VIOLATION NOTICE: “Analysts Set Retrophin, Inc. (RTRX) PT at $35.00” was first reported by Markets Daily and is the sole property of of Markets Daily. If you are viewing this article on another publication, it was illegally stolen and reposted in violation of United States and international trademark & copyright laws. The legal version of this article can be read at https://www.themarketsdaily.com/2017/09/11/analysts-set-retrophin-inc-rtrx-pt-at-35-00.html.
In related news, COO Neil F. Mcfarlane sold 1,378 shares of Retrophin stock in a transaction that occurred on Wednesday, August 16th. The shares were sold at an average price of $22.50, for a total transaction of $31,005.00. Following the transaction, the chief operating officer now directly owns 13,622 shares of the company’s stock, valued at $306,495. The sale was disclosed in a filing with the SEC, which is accessible through this link. Company insiders own 2.41% of the company’s stock.
Hedge funds have recently modified their holdings of the stock. SG Americas Securities LLC increased its holdings in Retrophin by 1.8% during the second quarter. SG Americas Securities LLC now owns 8,167 shares of the biopharmaceutical company’s stock valued at $158,000 after buying an additional 146 shares during the period. Legal & General Group Plc increased its holdings in Retrophin by 4.3% during the second quarter. Legal & General Group Plc now owns 8,664 shares of the biopharmaceutical company’s stock valued at $168,000 after buying an additional 355 shares during the period. Weiss Multi Strategy Advisers LLC purchased a new position in Retrophin during the first quarter valued at approximately $185,000. Dynamic Technology Lab Private Ltd purchased a new position in Retrophin during the first quarter valued at approximately $219,000. Finally, Fox Run Management L.L.C. purchased a new position in Retrophin during the second quarter valued at approximately $246,000.
Retrophin (NASDAQ:RTRX) traded up 0.25% on Wednesday, hitting $24.02. The company’s stock had a trading volume of 292,971 shares. Retrophin has a 12 month low of $15.55 and a 12 month high of $25.11. The firm has a 50 day moving average of $22.38 and a 200 day moving average of $19.53. The firm’s market cap is $922.01 million.
Retrophin (NASDAQ:RTRX) last posted its quarterly earnings results on Wednesday, August 9th. The biopharmaceutical company reported ($0.34) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.24) by $0.10. Retrophin had a negative net margin of 48.74% and a negative return on equity of 7.31%. The company had revenue of $38.80 million for the quarter, compared to the consensus estimate of $37.36 million. During the same period in the prior year, the firm posted $0.07 EPS. The business’s revenue was up 16.5% on a year-over-year basis. Equities research analysts forecast that Retrophin will post ($1.13) earnings per share for the current fiscal year.
Retrophin Company Profile
Retrophin, Inc is a biopharmaceutical company. The Company is focused on the development, acquisition and commercialization of therapies for the treatment of serious, catastrophic or rare diseases. The Company sells three products, including Chenodal (chenodeoxycholic acid), Cholbam (cholic acid) and Thiola (tiopronin).
Receive News & Ratings for Retrophin Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Retrophin Inc. and related companies with MarketBeat.com's FREE daily email newsletter.